FIG. 2. Wild-type (WT) Spike-receptor binding domain (S-RBD) IgG
and surrogate virus neutralization test (sVNT) results after COVID-19
vaccination by disease category. A and B show S-RBD IgG and sVNT
results respectively in five disease categories (combined, humoral,
innate, dysregulation and phagocytic) after 2 doses, while C and D show
S-RBD and sVNT results after 3 doses. Geometric means (GM) are shown
with centre lines and stated above each column. Limits of detection and
quantification (LOD and LOQ) were drawn as grey lines. Number of
analyzed available samples (n) are also stated above each column. A and
B included 2 patients (one each in combined and innate) who received
first 2 doses intradermally and their datapoints were shown as darkened
squares. C and D also included 4 patients (1 each in combined, humoral,
innate and dysregulation) who received their third dose intradermally
and their datapoints were also shown as darkened squares.
Table 2. Antibody responses in IEI patients. * denotes results
samples taken after breakthrough infection. Negative S-RBD IgG, WT sVNT
and BA.1 sVNT results were imputed as 0.25, 15 and 10 respectively. B –
BNT162b2, C – CoronaVac, M (route) – intramuscular, D – intradermal.